Kamada (NASDAQ:KMDA) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Kamada (NASDAQ:KMDAGet Rating) in a research note released on Monday morning. The brokerage issued a buy rating on the biotechnology company’s stock.

Kamada Stock Performance

KMDA opened at $4.30 on Monday. The firm has a market capitalization of $192.64 million, a P/E ratio of -18.69 and a beta of 0.94. The stock’s 50 day moving average price is $4.48 and its two-hundred day moving average price is $4.68. The company has a quick ratio of 1.09, a current ratio of 2.39 and a debt-to-equity ratio of 0.09. Kamada has a 12-month low of $4.11 and a 12-month high of $6.96.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KMDA. Group One Trading L.P. lifted its holdings in shares of Kamada by 103.7% in the first quarter. Group One Trading L.P. now owns 11,064 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 307,831 shares in the last quarter. Citigroup Inc. grew its position in shares of Kamada by 2,620.0% in the first quarter. Citigroup Inc. now owns 36,938 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 35,580 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Kamada by 151.1% in the first quarter. Goldman Sachs Group Inc. now owns 37,518 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 22,576 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Kamada by 32.5% during the first quarter. Dimensional Fund Advisors LP now owns 68,889 shares of the biotechnology company’s stock worth $380,000 after buying an additional 16,886 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Kamada by 3.1% during the first quarter. Vanguard Group Inc. now owns 779,451 shares of the biotechnology company’s stock worth $4,302,000 after buying an additional 23,768 shares in the last quarter.

Kamada Company Profile

(Get Rating)

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD.

Featured Stories

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.